title: Solifenacin and Tamsulosin Combination Therapy Decreases Urine Nerve Growth Factor/Creatinine Levels in Men.
abstract: To evaluate urinary nerve growth factor (NGF)/creatinine (Cr) levels from men with symptomatic lower urinary tract symptoms (LUTS) and measure the effect of combination therapy with solifenacin and tamsulosin.
  
  
  
  From January 2012 to February 2014, all male patients referred for evaluation and management of LUTS were screened for enrollment. In all subjects, urinary NGF and Cr levels were measured and normalized to the urinary Cr concentrations (NGF/Cr). Uroflow, postvoid residual, and symptom questionnaires were measured at baseline, 4 weeks, 8 weeks, and 12 weeks after starting combination therapy with solifenacin 5 mg and tamsulosin 0.4 mg. The primary endpoint was urinary NGF and NGF/Cr change from baseline compared with week 12.
  
  
  
  Ten patients were recruited into the study. Peak urine flow at baseline 20.3 ± 2.5 ml/s and postvoid residual 45.3 ± 13.6 ml did not significantly change with 3 months of combination treatment 14.9 ± 1.8 ml/s and 58.5 ± 23.9 ml. However, urine NGF/Cr (pg/mg) levels were significantly reduced following treatment with levels of 39.7 ± 6.6 at baseline to 17.9 ± 5.1 at 3 months (P value <.05). The decrease in urine NGF/Cr levels correlated with significant decreases in patient reported outcomes.
  
  
  
  Male patients with LUTS had decreased urinary NGF/Cr levels after treatment with combination solifenacin and tamsulosin in this novel pilot study. This corresponded with improvement in patient reported outcomes.
authors.affiliation: Department of Urology, Houston Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX. Electronic address: drrobertchan@gmail.com.
authors.forename: Robert
authors.initials: R
authors.lastname: Chan
authors.affiliation: Houston Methodist Research Institute, Houston, TX.
authors.forename: Alvaro
authors.initials: A
authors.lastname: Munoz
authors.affiliation: Baylor College of Medicine, Houston, TX.
authors.forename: Evan P
authors.initials: EP
authors.lastname: Wenker
authors.affiliation: Department of Urology, Houston Methodist Hospital, Houston, TX.
authors.forename: Melissa
authors.initials: M
authors.lastname: Whipple
authors.affiliation: Department of Urology, Houston Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX.
authors.forename: Brian
authors.initials: B
authors.lastname: Miles
authors.affiliation: Department of Urology, Houston Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX; Houston Methodist Research Institute, Houston, TX.
authors.forename: Timothy B
authors.initials: TB
authors.lastname: Boone
mesh_terms: D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D003404:Creatinine / Q000652:urine*; D004359:Drug Therapy, Combination; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D020932:Nerve Growth Factor / Q000652:urine*; D010865:Pilot Projects; D000069464:Solifenacin Succinate / Q000008:administration & dosage*; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin
chemical_list: D058668:Adrenergic alpha-1 Receptor Antagonists; D018727:Muscarinic Antagonists; D013449:Sulfonamides; D020932:Nerve Growth Factor; D003404:Creatinine; D000077409:Tamsulosin; D000069464:Solifenacin Succinate